Istabraq Saeed Abaas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Istabraq Saeed Abaas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alhasan Ali Jabbar
Department of Pharmacology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
1 shared publication - Entsar Hadi Jawad
Department of Pharmaceutics, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq
1 shared publication - Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
1 shared publication - Hassan A. Almoustafa
Universiti Malaya Research Center for Biopharmaceuticals and Advanced Therapeutics (UBAT), Pharmacology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
1 shared publication - Nawres Bahaa Mohammed
College of Dentistry, University of Al-Ameed, Karbala, Iraq
1 shared publication - Sarah Mohammed Altamimi
College of Dentistry, Al-Bayan University, Baghdad, Iraq
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
A review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessA review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.